References
- Carter SJ, Cápka V. (2008). Investigation of interaction between salmeterol and fluticasone propionate and its effect on quantitative accuracy of an LC/MS/MS assay in human plasma at low pg/mL concentrations. J Chromatogr B Analyt Technol Biomed Life Sci 876:163–9
- Cates CJ, Lasserson TJ. (2012). Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events. Cochrane Database Syst Rev 3:CD007695
- Chang C, Bahadduri PM, Polli JE, et al. (2006). Rapid identification of P-glycoprotein substrates and inhibitors. Drug Metab Dispos 34:1976–84
- Costa P, Sousa Lobo JM. (2001). Modeling and comparison of dissolution profiles. Eur J Pharm Sci 13:123–33
- Daley-Yates PT, Parkins DA. (2011). Systemic bioavailability of hydrofluoroalkane formulations containing fluticasone propionate and salmeterol. Br J Clin Pharmacol 72:353–4
- De La Vega JC, Elischer P, Schneider T, Häfeli UO. (2013). Uniform polymer microspheres: monodispersity criteria, methods of formation and applications. Nanomedicine (Lond) 8:265–85
- des Rieux A, Fievez V, Garinot M, et al. (2006). Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J Control Release 116:1–27
- Fahmy TM, Fong PM, Goyal A, Saltzman WM. (2005). Targeted for drug delivery. Mater Today 8:18–26
- Fahmy TM, Fong PM, Park J, et al. (2007). Nanosystems for simultaneous imaging and drug delivery to T cells. AAPS J 9:171–80
- Farokhzad OC, Cheng J, Teply BA, et al. (2006). Nanotechnology in cancer treatment and detection. PNAS 103:6315–20
- Gupta S, Jain A, Chakraborty M, et al. (2013). Oral delivery of therapeutic proteins and peptides: a review on recent developments. Drug Deliv 20:237–46
- Harrison LI, Novak CC, Needham MJ, Ratner P. (2011). Comparative pulmonary function and pharmacokinetics of fluticasone propionate and salmeterol xinafoate delivered by two dry powder inhalers to patients with asthma. J Aerosol Med Pulm Drug Deliv 24:245–52
- Hu L, Zhang H, Song W. (2013). An overview of preparation and evaluation sustained-release injectable microspheres. J Microencapsul 30:369–82
- Huang YY, Chung TW, Tzeng TW. (1997). Drug release from PLA/PEG microparticulates. Int J Pharm 156:9–15
- Islam MA, Firdous J, Choi YJ, Yun CH, Cho CS. (2012). Design and application of chitosan microspheres as oral and nasal vaccine carriers: an updated review. Int J Nanomedicine 7:6077–93
- Kim SH, Jeong JH, Chun KW, Park TG. (2005). Target-specific cellular uptake of PLGA nanoparticles coated with poly(l-lysine)–poly(ethylene glycol), folate conjugate. Langmuir 21:8852–7
- Moghimi SM, Hunter AC, Murray JC. (2001). Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 53:283–318
- Schaefer MJ, Singh J. (2002). Effect of tricaprin on the physical characteristics and in vitro release of etoposide from PLGA microspheres. Biomaterials 23:3465–71
- Spencer S, Karner C, Cates CJ, Evans DJ. (2011). Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 12:CD007033
- Takeuchi H, Yamamoto H, Kawashima Y. (2001). Mucoadhesive nanoparticulate systems for peptide drug delivery. Adv Drug Deliv Rev 47:39–54
- Yen SY, Sung KC, Wang JJ, et al. (2001). Controlled release of nalbuphine propionate from biodegradable microspheres: in vitro and in vivo studies. Int J Pharm 220:91–9
- Yin Y, Chen D, Qiao M, et al. (2006). Preparation and evaluation of lectin-conjugated PLGA nanoparticles for oral delivery of thymopentin. J Control Release 116:337–45
- Zhang Z, Bi X, Li H, et al. (2011). Enhanced targeting efficiency of PLGA microspheres loaded with Lornoxicam for intra-articular administration. Drug Deliv 18:536–44
- Zolnik BS, Burgess DJ. (2007). Effect of acidic pH on PLGA microsphere degradation and release. J Control Release 122:338–44